Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
50–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age between 50 and 80 years
National Institute on Aging/Alzheimer's Association core clinical criteria for probable Alzheimer's disease (AD) dementia or mild cognitive impairment (prodromal AD)
Evidence of the AD pathological process, by a positive amyloid assessment either on cerebrospinal fluid Aβ1-42 OR amyloid positron emission tomography (PET) scan. Historical amyloid PET scans may be accepted in some cases
Mild AD symptomatology, as defined by a screening Mini-Mental State Examination score of \>= 20 points and Clinical Dementia Rating (CDR) -Global Score of 0.5 or 1
Abnormal memory function at screening
Availability of a person with sufficient contact with the participant to be able to provide accurate information on the participant's cognitive and functional ability
You may not be if
Pregnant or breastfeeding
Inability to tolerate magnetic resonance imaging (MRI) procedures or contraindication to MRI
Contraindications to both PET imaging and lumbar dural puncture (must be able to undergo at least one of these procedures to be eligible)
Residence in a skilled nursing facility
Any serious medical condition or abnormality in clinical laboratory tests that remains abnormal on retest and, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or bias the assessment of the clinical or mental status of the participant to a significant degree
Any evidence of a condition other than AD that may affect cognition
Alcohol or substance abuse within the past 2 years
Use of any experimental therapy within 90 days or 5 half-lives prior to screening, whichever is greater and any passive immunotherapy (immunoglobulin) against tau, except use of RO7105705 in Genentech Study GN39058, as long as the last dose was at least 90 days prior to screening
Use of any passive immunotherapy (immunoglobulin) against Aβ, unless the last dose was at least 1 year prior to screening and any active immunotherapy (vaccine) that is under evaluation to prevent or postpone cognitive decline
Any previous treatment with medications specifically intended to treat Parkinsonian symptoms or any other neurodegenerative disorder within 1 year of screening
Systemic immunosuppressive therapy within 12 months of screening through the entire study period
Typical antipsychotic or neuroleptic medication within 6 months of screening
Daily treatment with any of the following classes of medication, except for intermittent short-term use, which is permitted except within 2 days or 5 half-lives (whichever is longer) prior to any COA: atypical antipsychotics, opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally-acting antihistamine or anticholinergic activity
Stimulant medications, unless the dose has been stable within the 6 months prior to screening and is expected to be stable throughout the study
Clareo Health | A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
